AKT1 and colorectal carcinoma: Periplocymarin (Figure 2, 16), a cardiac glycoside derived from Periploca sepium, exhibits potential anticancer properties (Cheng Y. et al., 2021; Cheng et al., 2021b) demonstrated that this compound exerts therapeutic effects against CRC through impairment of PI3K/AKT pathway functionality, which mechanism involves triggering apoptotic processes and inducing cell cycle arrest at the G0/G1 phase, achieved through suppression of IRS1 expression and phosphorylation of PI3K/AKT proteins.